Burden of cardiovascular disease in Japanese cancer patients and survivors: a single cancer-center study in Niigata City
Cardiovascular disease (CVD) and cancer are major causes of death in Japan. As most CVDs are chronic and often aggravate, long-term follow-up is necessary. Although some cancer patients and survivors have CVD, its prognostic significance and prevalence are unknown. Therefore, we conducted a retrospective study at our center to determine the prevalence of cancer patients with CVD.
In 2015, our 10-year (2005–2014) cancer registry was summarized. Comorbidities including left ventricular dysfunction, atrial fibrillation (AF), ischemic heart disease, aortic stenosis, venous thromboembolism (VTE), and elevation of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) were examined.
In total, 26,235 de novo cancer patients were registered and 16,130 survived until January 1, 2015. The 5-year survival rate was 64.0% for all cancer patients and 44.2% for cancer patients with CVD. Cox proportional hazards analysis adjusting for age, cancer stage, and body mass index revealed that AF [hazard ratio (HR) 1.219, male; P = 0.038], VTE (HR 1.517, male; P = 0.003 and HR 2.089, female; P < 0.001), and NT-proBNP elevation (HR 1.861, female; P = 0.002) were significantly associated with death. The CVD prevalence among cancer survivors in 2015 was 8.7% vs 3.5% for males vs females. AF was the most common CVD (prevalence: male, 4.0%; female, 1.0%). The prevalence of most CVD in adults increased progressively with age, with male predominance (12.1% for male and 7.5% for female patients in the 80 s age group).
One in 10 elderly cancer survivors has serious CVD. AF, VTE, and heart failure were critical comorbidities. Cardiologists and cancer-care providers should recognize CVD presence and monitor patients closely, providing medications or interventions concurrently with cancer therapy.
KeywordsAtrial fibrillation Venous thromboembolism N-terminal prohormone of brain natriuretic peptide Heart failure
We are indebted to Chika Sekine and Tomomi Fujita (cancer registry) for their superb assistance with the datasets; Sumika Ishigaki, Satoko Sakakibara, Chika Yumoto, Megumi Kira, Keiko Henmi (echocardiography laboratory) for performing electrocardiography, echocardiography, and vascular echo; Naho Sasaki and Masaki Yoshino (Department of Pharmacy) for pharmacological information; Dr. Yoshinobu Okada for treating cancer patients with CVD.
Compliance with ethical standards
Conflict of interest
No author has any conflict of interest.
- 2.Mortality by cause of death (2018) Statistics Bureau, Ministry of internal affairs and communications. http://www.stat.go.jp/data/sekai/0116.htm#c14. Accessed July 2018
- 4.American Cancer Society Cancer Facts & Figs (2017) American Cancer Society, Atlanta. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html. Accessed July 2018
- 5.Goff DC Jr, Lloyd-Jones DM, Bennett G, American College of Cardiology/American Heart Association Task Force on Practice Guidelines et al (2014) 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129:S74–S75CrossRefGoogle Scholar
- 8.Ten years survival of cancer patients in hospital group of Japanese Association of Clinical Cancer Centers (2016) Press release published by National Cancer Center Japan in January 26. https://www.ncc.go.jp/jp/information/pr_release/2016/0120/index.html. Accessed July 2018 (Japanese)
- 9.Paulus WJ, Tschöpe C, Sanderson JE et al (2007) How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28:2539–2550CrossRefPubMedCentralGoogle Scholar
- 10.Tsutsui H, Isobe M, Ito H, JCS Joint Working Group et al (2017) Guidelines for diagnosis and treatment of acute and chronic heart failure (JCS 2017/JHFS 2017). http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf. Accessed July 2018 (Japanese)
- 11.Okita Y, Okada K, Otsuji Y, JCS Joint Working Group et al (2012) Guidelines for surgical and interventional treatment of valvular heart disease (JCS 2012). http://www.j-circ.or.jp/guideline/pdf/JCS2012_ookita_h.pdf. Accessed January 2018 (Japanese)
- 14.Okura Y, Ishigaki S, Sakakibara S, et al. (2018) Prognosis of cancer patients with aortic stenosis under optimal cancer therapies and conservative cardiac treatments: a single cancer center study with 92 consecutive patients. Int heart J. https://doi.org/10.1536/ihj.17-320 (in press) CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Benjamin EJ, Blaha MJ, Chiuve SE, American Heart Association Statistics Committee and Stroke Statistics Subcommittee et al (2017) Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 135:e146–e603. https://doi.org/10.1161/CIR.0000000000000485 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Tei C, Amano K, Ueno K, JCS Joint Working Group et al (2010). guidelines for gender-specific cardiovascular disease (JCS2010). Circ J 74(Suppl. II). http://www.j-circ.or.jp/guideline/pdf/JCS2010tei.h.pdf. Accessed January 2018 (Japanese)
- 29.Chen HH, Colucci WS (2017) Natriuretic peptide measurement in non-heart failure settings. https://www.uptodate.com/contents/natriuretic-peptide-measurement-in-non-heart-failure-settings (December 29, 2017)
- 31.Christ M, Laule-Kilian K, Hochholzer W et al (2006) Gender-specific risk stratification with B-type natriuretic peptide levels in patients with acute dyspnea: insights from the B-type natriuretic peptide for acute shortness of breath evaluation study. J Am Coll Cardiol 48:1808–1812CrossRefGoogle Scholar
- 32.Sobue T, Saika K (2015) The 42nd scientific meeting perspectives of internal medicine; considerations to treatment and care of cancer by internists in the era of increasing cancer mortality 2. Fruits of basic research on Cancer; 1) Cancer epidemiology–trends of cancer statistics based on cancer registry]. Nihon Naika Gakkai Zasshi 104:417–425 (Japanese) CrossRefPubMedCentralGoogle Scholar
- 34.Cancer mortality in each prefecture in Japan (2018) Cancer registry and statistics. Cancer Information Service, National Cancer Center, Japan. https://ganjoho.jp/reg_stat/statistics /dl/index.html#survival. Accessed July 2018
- 35.Matsuda A, Katano K (2012) Cancer mortality in each prefecture. In: Sobue T (ed) Gan Toukei Hakusho 2012. Shinohara shuppan shinsha, Tokyo, pp 15–42 (Japanese) Google Scholar